 Proactive Investors USA & Canada | Afinitor Study Meets Primary Endpoint Drug Discovery & Development A Phase 3 study of Novartis' Afinitor (everolimus) tabletsin patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, ... Novartis drug Afinitor® effective in patients with non-cancerous kidney ... Novartis' Afinitor Study Show Positive Results In Kidney Tumors |
